Alcon bought Aerie Pharmaceuticals Aerie Pharmaceuticals from 11/22/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Alcon completed its acquisition of Aerie Pharmaceuticals for $770 million, or 15.25 per share.

Aerie Pharmaceuticals

Review

Source:

{source} pictogram

investor.alcon.com

Vladimir Petenev

News editor

Write your comment first

News feed

Board of Directors of Magnitogorsk Iron and Steel Works recommended that dividends be paid for 2023

4/27/24 MAGN

Volgogradenergosbyt reported for 3 months of 2024 by RAS

4/27/24 VGSB

Board of Directors of Europlan recommended that dividends be paid for 2023

4/27/24 LEAS

Board of Directors of UK Arsagera recommended that dividends be paid for 2023

4/27/24 ARSA

KSC reported for 2023 by IFRS

4/27/24 KTSB

Yakovlev reported for 2023 by IFRS

4/27/24 IRKT

TNS Energo Nizhny Novgorod reported for 3 months of 2024 under RAS

4/27/24 NNSB

Polyus reported for 3 months of 2024 by RAS

4/27/24 PLZL

LSR reported for 3 months of 2024 by RAS

4/27/24 LSRG

KuibyshevAzot reported for 3 months of 2024 by RAS

4/27/24 KAZT